- Home
- NI vs BIIB Comparison
NI vs BIIB Comparison
Compare NI & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NI
- BIIB
- Stock Information
- Founded
- NI 1912
- BIIB 1978
- Country
- NI United States
- BIIB United States
- Employees
- NI N/A
- BIIB N/A
- Industry
- NI Power Generation
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- NI Utilities
- BIIB Health Care
- Exchange
- NI Nasdaq
- BIIB Nasdaq
- Market Cap
- NI 20.1B
- BIIB 18.7B
- IPO Year
- NI N/A
- BIIB 1991
- Fundamental
- Price
- NI $40.33
- BIIB $140.67
- Analyst Decision
- NI Buy
- BIIB Buy
- Analyst Count
- NI 8
- BIIB 27
- Target Price
- NI $43.88
- BIIB $188.09
- AVG Volume (30 Days)
- NI 4.1M
- BIIB 1.4M
- Earning Date
- NI 10-29-2025
- BIIB 10-29-2025
- Dividend Yield
- NI 2.78%
- BIIB N/A
- EPS Growth
- NI 16.92
- BIIB 31.67
- EPS
- NI 1.90
- BIIB 10.45
- Revenue
- NI $6,130,300,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- NI $18.44
- BIIB $2.00
- Revenue Next Year
- NI $3.81
- BIIB N/A
- P/E Ratio
- NI $21.23
- BIIB $13.46
- Revenue Growth
- NI 16.98
- BIIB 3.36
- 52 Week Low
- NI $33.03
- BIIB $110.04
- 52 Week High
- NI $43.51
- BIIB $205.19
- Technical
- Relative Strength Index (RSI)
- NI 37.34
- BIIB 59.82
- Support Level
- NI $38.45
- BIIB $137.14
- Resistance Level
- NI $42.39
- BIIB $145.27
- Average True Range (ATR)
- NI 0.77
- BIIB 3.85
- MACD
- NI -0.31
- BIIB 0.28
- Stochastic Oscillator
- NI 41.32
- BIIB 66.55
About NI NiSource Inc
NiSource is one of the nation's largest natural gas distribution companies with 3.2 million customers in Indiana, Kentucky, Maryland, Ohio, Pennsylvania, and Virginia. NiSource's electric utility transmits and distributes electricity in northern Indiana to about 500,000 customers. The regulated electric utility also owns more than 3,000 megawatts of generation capacity, including coal, natural gas, and renewable energy.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.